Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02201212 · ClinicalTrials.gov registry record · Phase 2

Everolimus for Cancer With TSC1 or TSC2 Mutation

A Phase 2 study of Tuberous Sclerosis Complex and TSC1, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target
2
Study locations

NCT02201212 is a Phase 2 study of Tuberous Sclerosis Complex and TSC1 that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants, below the 154-participant average among 8 other Tuberous Sclerosis Complex trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02201212, a Phase 2 study of Tuberous Sclerosis Complex and TSC1, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

In this research study, the investigators are evaluating the clinical benefit of everolimus in cancer patients with inactivating TSC1 or TSC2 mutations or activating MTOR mutations. This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug called everolimus to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug is being studied. It also means that the FDA (the U.S. Food and Drug Administration) has not yet approved everolimus for your type of cancer. Everolimus is a drug that may stop cancer cells from growing by blocking an important factor (mTOR) involved in the growth of cells. This drug has been used in treatment for other cancers and is approved by the Food and Drug Administration for treatment of several types of cancer, including renal cell carcinoma. Treatment with this drug has been associated with responses in some patients whose cancers had mutations in TSC1 or TSC2. The investigators think that patients whose tumors have mutations in TSC1 or TSC2 may have a good chance of responding to treatment with drugs like everolimus.

Conditions Studied

Tuberous Sclerosis Complex TSC1 TSC2 MTOR

Interventions

  • DRUG Everolimus

Study Locations (2)

Massachusetts

  • Dana Farber Cancer Institute - Boston

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2014-09
Est. Completion 2019-06
Phase Phase 2

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02201212

The ClinicalTrials.gov registry entry for NCT02201212 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 154-participant average among 8 other Tuberous Sclerosis Complex trials with a reported enrollment target (81% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Tuberous Sclerosis Complex appearing as the primary indexed condition, and to 1 intervention - of which Everolimus is the first listed.

NCT02201212 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT02201212 about?

NCT02201212 is a clinical study titled "Everolimus for Cancer With TSC1 or TSC2 Mutation". In this research study, the investigators are evaluating the clinical benefit of everolimus in cancer patients with inactivating TSC1 or TSC2 mutations or activating MTOR mutations. This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug...

What is the current status of trial NCT02201212?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2014-09. Estimated completion is 2019-06.

What conditions does trial NCT02201212 study?

This clinical trial studies the following conditions: Tuberous Sclerosis Complex, TSC1, TSC2, MTOR.

What interventions are being tested in trial NCT02201212?

The interventions under investigation include: Everolimus (DRUG).

Who is sponsoring clinical trial NCT02201212?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02201212 being conducted?

This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Tuberous Sclerosis Complex

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Tuberous Sclerosis Complex

All registered trials for this condition

TSC1

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.